115 related articles for article (PubMed ID: 4002836)
1. Control of herpes simplex virus infections of the genital tract by vaccination.
Buchan A; Skinner GR; Fuller A; Hartley C; Hallworth J; Stocker D; Melling J; Wiblin C
Vaccine; 1985 Mar; 3(1):49-53. PubMed ID: 4002836
[TBL] [Abstract][Full Text] [Related]
2. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group.
Corey L; Langenberg AG; Ashley R; Sekulovich RE; Izu AE; Douglas JM; Handsfield HH; Warren T; Marr L; Tyring S; DiCarlo R; Adimora AA; Leone P; Dekker CL; Burke RL; Leong WP; Straus SE
JAMA; 1999 Jul; 282(4):331-40. PubMed ID: 10432030
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of Skinner herpes simplex vaccine towards modulation of herpes genitalis; report of a prospective double-blind placebo-controlled trial.
Skinner GR; Turyk ME; Benson CA; Wilbanks GD; Heseltine P; Galpin J; Kaufman R; Goldberg L; Hartley CE; Buchan A
Med Microbiol Immunol; 1997 Jun; 186(1):31-6. PubMed ID: 9255764
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial.
Straus SE; Wald A; Kost RG; McKenzie R; Langenberg AG; Hohman P; Lekstrom J; Cox E; Nakamura M; Sekulovich R; Izu A; Dekker C; Corey L
J Infect Dis; 1997 Nov; 176(5):1129-34. PubMed ID: 9359709
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of vaccine Ac NFU1 (S-) MRC 5 given after an initial clinical episode in the prevention of herpes genitalis.
Woodman CB; Buchan A; Fuller A; Hartley C; Skinner GR; Stocker D; Sugrue D; Clay JC; Wilkins G; Wiblin C
Br J Vener Dis; 1983 Oct; 59(5):311-3. PubMed ID: 6311322
[TBL] [Abstract][Full Text] [Related]
6. Report of twelve years experience in open study of Skinner herpes simplex vaccine towards prevention of herpes genitalis.
Skinner GR; Fink C; Melling J; Wiblin C; Thornton B; Hallworth J; Gardner W; McLeish P; Hartley C; Buchan A
Med Microbiol Immunol; 1992; 180(6):305-20. PubMed ID: 1549071
[TBL] [Abstract][Full Text] [Related]
7. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection.
Mertz GJ; Ashley R; Burke RL; Benedetti J; Critchlow C; Jones CC; Corey L
J Infect Dis; 1990 Apr; 161(4):653-60. PubMed ID: 2181031
[TBL] [Abstract][Full Text] [Related]
8. Early experience with "antigenoid" vaccine Ac NFU1(S-) MRC towards prevention or modification of herpes genitalis.
Skinner GR; Woodman C; Hartley C; Buchan A; Fuller A; Wiblin C; Wilkins G; Melling J
Dev Biol Stand; 1982; 52():333-44. PubMed ID: 6299842
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of herpes simplex virus vaccines in animals: the guinea pig vaginal model.
Stanberry LR
Rev Infect Dis; 1991; 13 Suppl 11():S920-3. PubMed ID: 1664129
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes.
Stanberry LR; Bernstein DI; Burke RL; Pachl C; Myers MG
J Infect Dis; 1987 May; 155(5):914-20. PubMed ID: 3031173
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of vaccination with Skinner vaccine towards the prevention of herpes simplex virus induced cervical carcinoma in an experimental mouse model.
Chen MH; Zhou Z; Hartley CE; Cowan M; Skinner GR
Vaccine; 1986 Dec; 4(4):249-52. PubMed ID: 3026107
[TBL] [Abstract][Full Text] [Related]
12. Hypothetical vaccination of the Dutch population with a herpes simplex virus vaccine: estimation of the profitability using a demographic projection model.
Bos CA
Vaccine; 1988 Aug; 6(4):309-14. PubMed ID: 2847437
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial.
; Abu-Elyazeed RR; Heineman T; Dubin G; Fourneau M; Leroux-Roels I; Leroux-Roels G; Richardus JH; Ostergaard L; Diez-Domingo J; Poder A; Van Damme P; Romanowski B; Blatter M; Silfverdal SA; Berglund J; Josefsson A; Cunningham AL; Flodmark CE; Tragiannidis A; Dobson S; Olafsson J; Puig-Barbera J; Mendez M; Barton S; Bernstein D; Mares J; Ratner P
Vaccine; 2013 Dec; 31(51):6136-43. PubMed ID: 23850416
[TBL] [Abstract][Full Text] [Related]
14. Seventeen years of application of herpes vaccines in Bulgaria.
Dundarov S; Andonov P
Acta Virol; 1994 Aug; 38(4):205-8. PubMed ID: 7879710
[TBL] [Abstract][Full Text] [Related]
15. Control of STDs--the role of prophylactic vaccines against herpes simplex virus.
Stanberry LR
Sex Transm Infect; 1998 Dec; 74(6):391-4. PubMed ID: 10195045
[TBL] [Abstract][Full Text] [Related]
16. Herpes simplex virus glycoprotein treatment of recurrent genital herpes.
Stanberry LR; Burke R; Myers MG
J Infect Dis; 1988 Jan; 157(1):156-63. PubMed ID: 2826603
[TBL] [Abstract][Full Text] [Related]
17. Effects of Different Doses of GEN-003, a Therapeutic Vaccine for Genital Herpes Simplex Virus-2, on Viral Shedding and Lesions: Results of a Randomized Placebo-Controlled Trial.
Van Wagoner N; Fife K; Leone PA; Bernstein DI; Warren T; Panther L; Novak RM; Beigi R; Kriesel J; Tyring S; Koltun W; Lucksinger G; Morris A; Zhang B; McNeil LK; Tasker S; Hetherington S; Wald A
J Infect Dis; 2018 Nov; 218(12):1890-1899. PubMed ID: 29982727
[TBL] [Abstract][Full Text] [Related]
18. Genital herpes simplex virus infections: current concepts in diagnosis, therapy, and prevention.
Corey L; Holmes KK
Ann Intern Med; 1983 Jun; 98(6):973-83. PubMed ID: 6344713
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of recombinant glycoprotein D subunit vaccines on the development of primary, recurrent, and latent genital infections with herpes simplex virus type 2 in guinea pigs.
Berman PW; Vogt PE; Gregory T; Lasky LA; Kern ER
J Infect Dis; 1988 May; 157(5):897-902. PubMed ID: 2834467
[TBL] [Abstract][Full Text] [Related]
20. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects.
de Bruyn G; Vargas-Cortez M; Warren T; Tyring SK; Fife KH; Lalezari J; Brady RC; Shahmanesh M; Kinghorn G; Beutner KR; Patel R; Drehobl MA; Horner P; Kurtz TO; McDermott S; Wald A; Corey L
Vaccine; 2006 Feb; 24(7):914-20. PubMed ID: 16213066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
